Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04887961 | Reprab Study: PLD + Trabectedin Rechallenge(MITO36) | unknown | Phase 2 | 64 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04983550 | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | unknown | Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 30, 2021 |
| clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT04556539 | Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer | unknown | Phase 2 | 104 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 12, 2021 | clinicaltrials |
| NCT00703105 | Ovarian Dendritic Cell Vaccine Trial | unknown | Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04846842 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | unknown | Phase 2 | 46 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Apr 19, 2021 | clinicaltrials |
| NCT04828616 | Study of DP303c Injection in Patients With Advanced Ovarian Cancer | unknown | Phase 2 | 104 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 2, 2021 | clinicaltrials |
| NCT04815408 | PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer | unknown | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT04068974 | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer | unknown | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT02822157 | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer(CLIO) | unknown | Phase 2 | 160 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04661696 | Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. | unknown | Phase 2 | 75 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04651946 | Cell-free DNA Methylation for Epithelial Ovarian Cancer | unknown | Phase 2 | 400 | Lei LiOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04376073 | Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer(ANNIE) | unknown | Phase 2 | 40 | Jihong LiuOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04566952 | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer(ANLOLA) | unknown | Phase 2 | 68 | Xiaoxiang ChenOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT04590625 | Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer | unknown | Phase 2 | 58 | Zhongshan Hospital Xiamen UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03899610 | A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)(KGOG3046) | unknown | Phase 2 | 24 | Yonsei UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04504110 | 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04383977 | Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 12, 2020 | clinicaltrials |
| NCT04261465 | NUVOLA TRIAL Open-label Multicentre Study(NUVOLA) | unknown | Phase 2 | 35 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03556566 | Open Label Immunotherapy Trial for Ovarian Cancer(V3-OVA) | unknown | Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Aug 30, 2019 | clinicaltrials |
| NCT04055038 | Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)(EPITOC) | unknown | Phase 2 / Phase 3 | 164 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03942068 | Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 35 | Henan Cancer HospitalOTHER_GOV | 0 | May 8, 2019 | clinicaltrials |
| NCT03924882 | Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT02349958 | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy(HIPEC/IPHC) | unknown | Phase 2 | 200 | Bay Area Gynecology OncologyOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03916679 | MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03412526 | Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian | unknown | Phase 2 | 15 | Sheba Medical CenterOTHER_GOV | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03818282 | Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer(OC-01) | unknown | Phase 2 | 77 | Huazhong University of Science and TechnologyOTHER | 0 | Feb 26, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03618706 | Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer | unknown | Phase 2 | 107 | Yonsei UniversityOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT03611179 | Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer | unknown | Phase 2 | 40 | Nada Hassan SalahOTHER | 0 | Aug 2, 2018 | clinicaltrials |
| NCT03547375 | Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy | unknown | Phase 2 | 69 | Anhui Provincial HospitalOTHER_GOV | 0 | Jun 6, 2018 | clinicaltrials |
| NCT03539328 | Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer(MITO27) | unknown | Phase 2 | 138 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 29, 2018 | clinicaltrials |
| NCT03188159 | Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer | unknown | Phase 2 | 36 | National University Hospital, SingaporeOTHER | 2 | Mar 29, 2018 | clinicaltrials |
| NCT01650376 | Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer | unknown | Phase 1 / Phase 2 | 52 | Swedish Medical CenterOTHER | 1 | Mar 23, 2018 | clinicaltrials |
| NCT03393507 | A Study of Apatinib Treatment in for Advanced Ovarian Cancer | unknown | Phase 2 | 34 | The People's Hospital of LeshanOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT03335241 | Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer | unknown | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT03298074 | Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 60 | Yang ZhijunOTHER | 0 | Sep 29, 2017 | clinicaltrials |
| NCT02684318 | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Poveda, Andrés, M.D.INDIV | 1 | Jun 22, 2017 | clinicaltrials |
| NCT01600573 | Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) | unknown | Phase 1 / Phase 2 | 68 | JSehouliOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | unknown | Phase 1 / Phase 2 | 31 | NovoCure Ltd.INDUSTRY | 4 | Sep 21, 2016 | clinicaltrials |
| NCT02595021 | Total/Subtotal Colectomy in Ovarian Cancer | unknown | Phase 2 | 80 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jul 26, 2016 | clinicaltrials |
| NCT00660101 | Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer | unknown | Phase 1 / Phase 2 | 34 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT02188550 | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | unknown | Phase 2 | 20 | Sinai Hospital of BaltimoreOTHER | 1 | May 19, 2015 | clinicaltrials |
| NCT02435186 | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | unknown | Phase 2 | 100 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | May 6, 2015 | clinicaltrials |
| NCT00410462 | Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma | unknown | Phase 2 | 118 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Aug 8, 2014 | clinicaltrials |
| NCT00004206 | Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer | unknown | Phase 2 | — | University of LeicesterOTHER | 1 | Jun 24, 2014 | clinicaltrials |
| NCT02132988 | Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer | unknown | Phase 2 | 110 | Mackay Memorial HospitalOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00553683 | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | unknown | Phase 1 / Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00003064 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 1 / Phase 2 | 30 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Aug 9, 2021source: clinicaltrials